KR20180013603A - Alcohol detoxification composition comprising extract of natural herb - Google Patents
Alcohol detoxification composition comprising extract of natural herb Download PDFInfo
- Publication number
- KR20180013603A KR20180013603A KR1020160097548A KR20160097548A KR20180013603A KR 20180013603 A KR20180013603 A KR 20180013603A KR 1020160097548 A KR1020160097548 A KR 1020160097548A KR 20160097548 A KR20160097548 A KR 20160097548A KR 20180013603 A KR20180013603 A KR 20180013603A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- concentrate
- parts
- hot water
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title description 64
- 238000001784 detoxification Methods 0.000 title description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 50
- 206010019133 Hangover Diseases 0.000 claims abstract description 27
- 244000269722 Thea sinensis Species 0.000 claims abstract description 27
- 235000009569 green tea Nutrition 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 239000012141 concentrate Substances 0.000 claims description 39
- 239000012676 herbal extract Substances 0.000 claims description 29
- 235000013305 food Nutrition 0.000 claims description 20
- 235000013399 edible fruits Nutrition 0.000 claims description 14
- 229930003935 flavonoid Natural products 0.000 claims description 10
- 235000017173 flavonoids Nutrition 0.000 claims description 10
- 150000002215 flavonoids Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 241000167854 Bourreria succulenta Species 0.000 claims description 7
- 235000019693 cherries Nutrition 0.000 claims description 7
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 6
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 229940010454 licorice Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 235000008586 Hovenia Nutrition 0.000 claims 1
- 241000405398 Hovenia Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 39
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 16
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract description 16
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract description 16
- 102000007698 Alcohol dehydrogenase Human genes 0.000 abstract description 14
- 108010021809 Alcohol dehydrogenase Proteins 0.000 abstract description 14
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 235000008216 herbs Nutrition 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 30
- 235000008504 concentrate Nutrition 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 21
- 241000411851 herbal medicine Species 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000012153 distilled water Substances 0.000 description 17
- 235000013361 beverage Nutrition 0.000 description 14
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000002292 Radical scavenging effect Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- 238000003809 water extraction Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000035622 drinking Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 150000002989 phenols Chemical class 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 241000202807 Glycyrrhiza Species 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- 102100033816 Aldehyde dehydrogenase, mitochondrial Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000579185 Bucerotidae Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 description 2
- 241000269799 Perca fluviatilis Species 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 240000004246 Agave americana Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102100040069 Aldehyde dehydrogenase 1A1 Human genes 0.000 description 1
- 101710150756 Aldehyde dehydrogenase, mitochondrial Proteins 0.000 description 1
- 241000583531 Alpinia purpurata Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 244000010000 Hovenia dulcis Species 0.000 description 1
- 235000008584 Hovenia dulcis Nutrition 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004159 Potassium persulphate Substances 0.000 description 1
- 241001361634 Rhizoctonia Species 0.000 description 1
- 241000684075 Rhizoctonia sp. Species 0.000 description 1
- 241000534017 Saururus chinensis Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000019463 artificial additive Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- -1 phenol compound Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 235000019394 potassium persulphate Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 천연생약 추출물을 함유하는 숙취해소용 조성물, 보다 상세하게는, 녹차종자, 어성초 및 연잎 추출물을 유효성분으로 함유하는 알코올 분해 작용이 우수하고 복용이 용이한 숙취해소용 조성물에 관한 것이다.The present invention relates to a composition for hangover decomposition containing a natural herbal medicine extract, and more particularly, to a composition for hangover decay which contains an effective ingredient of green tea seeds, a herbaceous plant extract and a lotus leaf extract as an active ingredient and has an excellent alcohol decomposing action and is easy to take.
술은 역사적으로 오랫동안 인류사회에서 제조 및 음용되어 왔으며, 현재에 이르러서도 일부 종교문화권을 제외하면 대부분의 인류사회에서 보편적으로 제조 및 음용되고 있다. 특히 우리 나라의 경우에는 사회생활 중 관습적으로 행해지는 음주문화로 술에 대한 노출빈도가 잦으며, 이로 인한 간 손상 및 건강 악화가 사회적으로 문제가 되고 있다. 보건복지부 산하 한국보건사회연구원이 실시한 2001년도 국민건강 영양조사결과에 의하면, 우리나라 20세 이상 성인의 음주율이 69.8%이고, 건강에 문제가 있을 수 있는 중등도음주 초과자 비율은 20세 이상 성인의 30.6%, 음주자의 63.4%에 달하는 것으로 나타났다. 현대인들은 과량의 알코올 섭취로 인하여 갈증, 피로감, 컨디션 저하, 기억력 감퇴, 현기증, 소화 불량, 구토, 설사 등의 숙취로 고생하는 경우가 늘었고, 알코올 중독의 위험성도 증가했다.Alcohol has been historically produced and consumed in human society for a long time, and by now, except in some religious cultures, it has been universally manufactured and consumed in most human societies. Especially in our country, it is frequent exposure to alcohol as a customary drinking culture in social life, and liver damage and health deterioration resulting from it are becoming a social problem. According to the results of the 2001 National Health and Nutrition Survey conducted by the Korea Health & Social Research Institute under the Ministry of Health and Welfare, 69.8% of adults in Korea are over 20 years old, and 30.6% , And 63.4% of drinkers. Modern people have suffered from hangovers such as thirst, fatigue, depression, memory loss, dizziness, dyspepsia, vomiting, diarrhea, and increased risk of alcoholism due to excessive alcohol consumption.
정상적인 알코올 대사과정은, 알코올류가 섭취되는 경우 위장 또는 소장에서 흡수되어 10%가 호흡, 소변, 땀 등으로 배설되고 90%가 혈관 중으로 들어가 간장에서 대사된다. 먼저 알코올분해효소(Alcohole Dehydrogenase, ADH)에 의하여 아세트알데히드가 되며, 이것이 간세포에 존재하는 알데히드분해효소(Acetaldehyde Dehydrogenase, ALDH)에 의하여 아세트산으로 분해된 후 근육 또는 지방 조직 등으로 옮겨져 탄산가스와 물로 분해된다. 사람들이 숙취를 느끼는 주 원인이 되는 물질로 아세트알데히드가 대표적인 것으로 알려져 있는데, 아세트알데히드는 미주신경, 교감신경내의 구심성신경섬유를 자극하여 구토, 홍조, 어지러움, 박동수 및 호흡횟수의 증가 등의 증상을 나타내게 된다. 최근 연구 보고에서는 아세트알데히드 외에도 메탄올과 같은 독성 알코올에 의하여 백혈구가 자극받아 유도되는 염증반응 및 탈수현상 등이 종합적으로 작용하여 숙취를 일으키는 것으로 알려졌다.Normal alcohol metabolism is absorbed in the stomach or small intestine when alcohol is ingested, and 10% is excreted by breathing, urine, sweat, etc. 90% enters the blood vessels and metabolizes in the liver. Acetaldehyde dehydrogenase (ALDH) is decomposed into acetic acid and then transferred to muscle or fat tissue and decomposed with carbonic acid gas and water. The acetaldehyde is converted into acetaldehyde by Alcohol Dehydrogenase (ADH) do. Acetaldehyde is known to be a major cause of people feeling hangover. Acetaldehyde stimulates afferent nerve fibers in the vagus nerve and sympathetic nerves to cause symptoms such as vomiting, flushing, dizziness, Lt; / RTI > In recent research reports, it is known that besides acetaldehyde, inflammation reaction and dehydration which are induced by leukocyte stimulation by toxic alcohol such as methanol act collectively and cause hangover.
알데히드분해효소는 ALDH1 형과 ALDH2 형이 있는데 이 중 동양인은 일반적으로 서양인에 비해 ALDH2 형이 결핍되어 아세트알데히드의 산화가 느린 것으로 알려져 있다. 이에 따라 음주 후 다양한 숙취증상을 느끼는 것이 드물지 않으며, 이러한 음주후의 숙취증상을 저감 또는 방지하기 위하여 보다 인체에 미치는 부작용이 적으면서 효과가 뛰어난 숙취해소 조성물의 개발이 요구되고 있다. 음주로 인한 숙취를 효과적으로 해소하기 위한 조성물로 생약성분의 추출물 등을 포함하는 조성물이 시판되고 있으나, 일부 생약제를 함유하는 조성물이 권태감, 팽만감, 구토감 등을 유발하거나 또는 지나치게 고가의 생약제 성분을 포함하여 지나치게 높은 가격으로 판매되어 접근성이 어려운 점 등의 문제가 있다.Aldehyde degrading enzymes include ALDH1 type and ALDH2 type. Of these, Asian people generally have lower ALDH2 type than Western ones, and it is known that the oxidation of acetaldehyde is slow. Accordingly, it is not uncommon to feel various hangover symptoms after drinking, and in order to reduce or prevent hangover symptoms after such drinking, there is a demand for development of a hangover resolution composition which is less effective in reducing side effects on the human body. A composition containing an extract of a herbal composition or the like is commercially available as a composition for effectively relieving a hangover due to drinking, but a composition containing a herbal medicine may cause boredom, bloating, vomiting, or the like, There is a problem that it is sold at an excessively high price and is difficult to access.
녹차(green tea)는 항산화물질을 다량 함유하여 노화를 억제시키고, 피부 탄력증진 및 보습에 뛰어난 효과를 갖는 생약 성분으로 알려져 있다. 녹차에 포함된 카테킨은 항암 효과 및 혈당 억제 효과를 가지고 있는 것으로 알려져 있으며, 녹차 종자에 특히 풍부한 함량으로 포함되어 있는 것으로 알려져 있다.Green tea contains a large amount of antioxidants to inhibit aging, and is known as a herbal ingredient that has excellent effects on skin elasticity and moisturizing. Catechin contained in green tea is known to have anticancer effect and blood sugar suppressing effect, and it is known that it is contained in an especially rich content in green tea seeds.
어성초(Houttuyniae Herba)는 삼백초과의 다년생 식물로 아시아 지역의 동남부, 우리나라 및 일본에 널리 자생하여 예로부터 민간요법에 많이 이용되어 왔다. 폐농양, 폐렴, 창독 등을 치료하기 위한 외용 약재로 이용되어 왔다. Houttuyniae Herba ) is a perennial plant of Saururus chinensis, which has been widely used in folk medicine since ancient times in South East Asia, Korea and Japan. Lung abscess, pneumonia, and venereal disease.
연(Lotus)은 다년생의 수중식물로, 연잎은 항산화물질을 다량 함유하고 있으며, 해독작용, 항균작용 및 혈압강하 작용에 효과가 있는 것으로 알려져 있다.Lotus is a perennial aquatic plant. It is known that lotus leaf contains a large amount of antioxidant and is effective for detoxification, antimicrobial action and hypotensive action.
본 발명은 녹차종자, 어성초 및 연잎 추출물을 특정 조성비로 포함함으로써 음주로 인한 숙취 증상을 예방, 해소 또는 경감할 수 있는 식품 조성물을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a food composition which can prevent, relieve or alleviate a hangover symptom caused by drinking, by containing a green tea seed, a perch and a lotus leaf extract in a specific composition ratio.
본 발명에 따르면, 녹차종자 열수추출물 20 내지 30 중량부, 어성초 열수추출물 40 내지 60 중량부 및 연잎 열수추출물 20 내지 30 중량부로 혼합하여 제조되는 복합 생약 추출물을 유효성분으로 함유하는 것을 특징으로 하는 숙취해소용 식품 조성물이 제공된다.According to the present invention, there is provided a method for producing a hanging product comprising a complex herbal medicine extract, which is prepared by mixing 20 to 30 parts by weight of a green tea seed hot water extract, 40 to 60 parts by weight of a hot water extract of Horseshoe extract and 20 to 30 parts by weight of a hot water extract of A food composition for relief is provided.
또한, 상기 녹차종자 열수추출물, 어성초 열수추출물 및 연잎 열수추출물은 추출원 중량대비 10 내지 20 배수의 용매를 첨가하고 90 내지 100℃에서 2 내지 4시간동안 추출하여 제조될 수 있다.The green tea seed hydrothermal extract, Hodgson's hydrothermal extract, and Yeast Leaf hot-water extract may be prepared by adding a solvent of 10 to 20 times the weight of the extractant and extracting the mixture at 90 to 100 ° C for 2 to 4 hours.
또한, 상기 복합 생약 추출물은 플라보노이드 함량 5 내지 7wt%일 수 있다.The complex herbal extract may have a flavonoid content of 5 to 7 wt%.
또한, 과일농축액, 헛개나무열매 농축액, 매실 농축액, 감초 농축액, 아미노산, 비타민 및 감미제를 더 포함할 수 있다.In addition, it may further contain fruit concentrate, hornbill concentrate, plum concentrate, licorice concentrate, amino acid, vitamins and sweetening agent.
또한, 상기 과일농축액은 체리농축액일 수 있다.The fruit concentrate may be a cherry concentrate.
또한, 조성물 100중량부에 대하여 상기 복합 생약 추출물 1 내지 3 중량부, 과일농축액 0.5 내지 5 중량부, 헛개나무열매 농축액 1 내지 5 중량부, 매실 농축액 0.1 내지 1 중량부, 감초 농축액 0.01 내지 0.1 중량부, 아미노산 0.1 내지 0.5 중량부, 비타민 0.00001 내지 0.001 중량부 및 감미제 10 내지 15 중량부로 포함할 수 있다.1 to 3 parts by weight of the complex herb extract, 0.5 to 5 parts by weight of a fruit concentrate, 1 to 5 parts by weight of a Hovenous Fruit concentrate, 0.1 to 1 part by weight of a plum concentrate, 0.01 to 0.1 part by weight of a licorice concentrate, 0.1 to 0.5 parts by weight of amino acids, 0.00001 to 0.001 parts by weight of vitamins and 10 to 15 parts by weight of sweeteners.
또한, 상기 식품 조성물은 분말, 과립, 정제, 캅셀 또는 음료의 형태일 수 있다.The food composition may also be in the form of a powder, granules, tablets, capsules or drinks.
본 발명에 따른 녹차종자, 어성초 및 연잎 추출물을 특정 조성비로 포함하는 식품 조성물은 우수한 항산화활성을 나타내고 알코올 분해 효소 활성을 증진시킴으로써, 알코올 분해 대사를 촉진시키고 알코올 분해 중간산물에 의한 염증 반응을 저감시킬 수 있다. 이를 통하여, 숙취 증상의 예방, 해소 또는 경감에 있어 우수한 효능을 발휘할 수 있다.The food composition containing the green tea seeds, the perennial herb extract and the lotus leaf extract according to the present invention exhibits excellent antioxidative activity and promotes the activity of the alcohololytic enzyme, thereby promoting the alcohol degradation metabolism and reducing the inflammatory reaction caused by the alcohol decomposition intermediate product . Through this, excellent efficacy can be exhibited in preventing, resolving or alleviating hangover symptoms.
또한, 조직에 대한 독성을 나타내지 않아 인체에 대한 안전성이 우수하므로, 안전한 식품 조성물로 사용될 수 있다.In addition, since it does not show toxicity to tissues and is safe for human body, it can be used as a safe food composition.
또한, 합성 착향료 또는 보존료 등의 합성 첨가물을 포함하지 않으면서도 우수한 산미를 가져, 건강지향적이면서 음용이 용이한 기호도 높은 식품 조성물로 사용될 수 있다.In addition, it can be used as a food composition having a good acidity and containing no synthetic additives such as a synthetic flavoring agent or a preservative, and being highly health-oriented and easy to drink and highly desirable.
도 1은 복합 생약 추출물의 DPPH 라디칼 소거 활성을 측정한 결과를 나타낸 도이고,
도 2는 복합 생약 추출물의 ABTs 라디칼 소거 활성을 측정한 결과를 나타낸 도이고,
도 3은 본 발명의 복합 생약 추출물이 ADH 활성에 미치는 영향을 측정한 결과를 나타낸 도이고,
도 4는 본 발명의 복합 생약 추출물이 ALDH 활성에 미치는 영향을 측정한 결과를 나타낸 도이고,
도 5는 본 발명의 복합 생약 추출물의 전처리가 알코올 투여 후 혈중 에탄올 함량을 감소시키는 활성을 측정한 결과를 나타낸 도이고,
도 6은 본 발명의 복합 생약 추출물의 전처리가 알코올 투여 후 혈중 아세트알데히드 함량을 감소시키는 활성을 측정한 결과를 나타낸 도이고,
도 7은 본 발명의 복합 생약 추출물을 포함하는 식품 조성물의 기호도 관능 평가 결과를 나타낸 도이다.FIG. 1 is a graph showing the results of measuring the DPPH radical scavenging activity of the herbal medicine extract,
FIG. 2 is a graph showing the results of measuring the ABTs radical scavenging activity of the herbal medicine extract,
FIG. 3 is a graph showing the results of measuring the effect of the herbal medicine extract of the present invention on ADH activity,
FIG. 4 is a graph showing the results of measuring the effect of the herbal extract of the present invention on ALDH activity,
FIG. 5 is a graph showing the results of measuring the activity of decreasing the ethanol content in the blood after the alcohol treatment by the pretreatment of the herbal extract of the present invention,
FIG. 6 is a graph showing the results of measuring the activity of pretreatment of the herbal extract of the present invention to reduce acetaldehyde content in blood after administration of alcohol,
7 is a graph showing the taste and sensory evaluation results of the food composition containing the herbal extract of the present invention.
본 발명은 녹차종자 열수추출물 20 내지 30 중량부, 어성초 열수추출물 40 내지 60 중량부 및 연잎 열수추출물 20 내지 30 중량부로 혼합하여 제조되는 복합 생약 추출물을 유효성분으로 함유하는 것을 특징으로 하는 숙취해소용 식품 조성물에 관한 것이다.The present invention relates to a herbal medicine comprising a herbal extract comprising 20 to 30 parts by weight of a green tea seed hydrothermal extract, 40 to 60 parts by weight of a hydrothermal extract of Horseshoe cherry, and 20 to 30 parts by weight of a hot water extract of Leafyard as an active ingredient. ≪ / RTI >
이하, 본 발명에 대해 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 조성물은 녹차종자, 어성초 및 연잎 추출물을 혼합하여 제조되는 복합 생약 추출물을 유효성분으로 포함한다.The composition of the present invention contains an extract of a complex herbal medicine prepared by mixing green tea seeds, Rhizoctonia sp.
본 발명에 있어서, 상기 복합 생약 추출물에 포함되는 녹차종자, 어성초 및 연잎 추출물의 분리는 열수추출법을 이용하여 수행된다. 상세하게는, 상기 복합 생약 추출물에 포함되는 각 성분별로 추출원 중량대비 10 내지 20 배수의 물을 용매로 첨가하고, 90 내지 100℃에서 2 내지 4시간동안 열수추출하여 각 성분별 추출물을 분리할 수 있다. 본 발명에 따른 복합 생약 추출물에 포함되는 녹차종자, 어성초 및 연잎 추출물의 분리가 상기의 용매 첨가량, 온도 및 시간 조건 하에 수행되는 경우, 추출 시간을 저감시키면서 고농도, 고효율로 추출물의 분리를 최적화하여 생산성을 증대시킬 수 있다. 또한, 각 성분별 추출물에 포함되는 유효성분의 함량을 극대화함으로써 제조되는 복합 생약 추출물의 효능을 증대시킬 수 있다. 열수 추출을 위해 각 성분별 첨가되는 용매의 함량이 추출원 중량대비 10배수 미만이면 유효성분인 페놀 화합물 또는 플라보노이드의 추출 함량이 저감될 수 있고, 20배수 초과이면 열수 추출 후 유효성분을 포함하는 추출용액의 농도가 지나치게 낮아 건조 등 후처리에 오랜 시간 및 비용이 소요되는 문제가 발생할 수 있다. 바람직하게는, 제조되는 열수 추출물의 표준화를 위하여 각 성분별로 추출원 중량대비 15 내지 20 배수의 물을 용매로 첨가하는 것이 좋다. 열수 추출 온도가 90℃ 미만이면 유효성분의 추출률이 저하되어 추출시간이 증가하고 100℃ 초과이면 증발로 용매의 함량이 저감되어 유효성분의 추출 함량이 저감되는 문제가 발생할 수 있다. 상기와 같은 조건의 용매 첨가량 및 추출 온도조건 하에서 2 내지 4시간 동안 추출하여 유효성분을 높은 비율로 포함하는 열수 추출물을 제조할 수 있다. 상기 분리된 열수 추출물을 공지된 방법에 따라 여과, 감압, 농축 및 건조하여 고형상의 열수 추출물을 제조할 수 있다. 필요에 따라, 열수 추출을 위한 각 성분별 추출원을 통상의 방법에 의하여 절단, 건조 및 분쇄하여 준비할 수 있다. 본 발명의 복합 생약 추출물을 제조하기 위해 준비되는 상기 녹차종자 추출물은 EGC를 3000 내지 4000㎍/㎖ 함량으로 포함할 수 있다. 상기 어성초 추출물은 하이페로시드를 150 내지 250㎍/㎖ 함량으로 포함할 수 있다. 상기 연잎 추출물은 쿼세틴을 8000 내지 12000㎍/㎖ 함량으로 포함할 수 있다.In the present invention, the separation of the green tea seeds, the oriental herb and the lotus leaf extract contained in the herbal medicine extracts is carried out using a hot water extraction method. Specifically, water in an amount of 10 to 20 times the weight of the extracted raw material is added to each component contained in the herbal medicine extract, and the extract is separated by hot water extraction at 90 to 100 ° C for 2 to 4 hours . When the separation of the green tea seeds, the oriental herb and the lotus leaf extract contained in the herbal medicine extract according to the present invention is carried out under the above-mentioned solvent addition amount, temperature and time condition, the extraction of the extract is optimized with high concentration and high efficiency, Can be increased. In addition, by maximizing the content of the active ingredient contained in the extract of each ingredient, the efficacy of the herbal extract of the present invention can be increased. If the content of the solvent added to each component is less than 10 times the weight of the extracted raw material for hot water extraction, the extraction content of the active ingredient, phenol compound or flavonoid, may be reduced. If the content is more than 20 times the extraction amount, The concentration of the solution is too low, which may cause a long time and cost for post-treatment such as drying. Preferably, for the standardization of the hot-water extract to be produced, it is preferable to add 15 to 20 times of water to each ingredient in a solvent as the weight of the extract. If the hot water extraction temperature is lower than 90 ° C, the extraction rate of the active ingredient lowers and the extraction time increases. If the hot water extraction temperature exceeds 100 ° C, the content of the solvent may be reduced by evaporation, thereby reducing the extraction amount of the active ingredient. The hot water extract containing the active ingredient at a high ratio can be prepared by extracting for 2 to 4 hours under the condition of the solvent addition amount and the extraction temperature as described above. The separated hot-water extract can be filtered, reduced in pressure, concentrated and dried according to a known method to produce a hot-water-extract of solid form. If necessary, the extraction source for each component for hot water extraction can be prepared by cutting, drying and crushing by a conventional method. The green tea seed extract prepared for preparing the herbal extract of the present invention may contain EGC in an amount of 3000 to 4000 μg / ml. The perennial herb extract may contain heparoside in an amount of 150 to 250 μg / ml. The extract of the lotus leaf can contain quercetin in an amount of 8000 to 12000 g / ml.
본 발명에 있어서, 상기 복합 생약 추출물은 녹차종자 열수 추출물 20 내지 30 중량부, 어성초 열수 추출물 40 내지 60 중량부 및 연잎 추출물 20 내지 30 중량부로 포함한다. 본 발명의 복합 생약 추출물이 각 성분을 상기의 중량비로 포함하는 경우 효능을 나타내는 유효성분인 페놀성 화합물 7wt% 이상, 플라보노이드 5wt% 이상의 높은 함량으로 포함하고 우수한 항산화 활성 및 알코올 분해 효소의 활성 증진 효과를 나타내, 숙취해소 효능을 극대화할 수 있다.In the present invention, the complex herbal medicine extract comprises 20 to 30 parts by weight of green tea seed hydrothermal extract, 40 to 60 parts by weight of hydrothermal extract and 20 to 30 parts by weight of lotus leaf extract. When the herbal extract of the present invention contains each component in the above-mentioned weight ratio, it contains 7 wt% or more of a phenolic compound, which is an effective ingredient showing efficacy, and 5 wt% or more of a flavonoid, and exhibits excellent antioxidative activity and promoting activity of an alcoholase To maximize the effect of hangover resolution.
본 발명에 따른 복합 생약 추출물을 포함하는 조성물은 항산화 활성을 가져 알코올 체내 분해 중 생성되는 아세트알데히드 및 메탄올에 의한 염증유발 숙취증상을 저감시킬 수 있다. 또한, 알코올의 체내 분해에 관여하는 효소의 활성을 증가시킴으로써 숙취증상을 저감시킬 수 있다. 상기 복합 생약 추출물을 포함하는 조성물을 알코올의 섭취 전·후로 경구투여하여 숙취증상의 예방, 저감 및 해소 효과를 나타낼 수 있으며, 또한, 알코올에 의한 간 손상을 저하시키는 간보호 효과를 가진다. 상기 숙취증상으로는 음주후의 갈증, 피로감, 컨디션 저하, 기억력 감퇴, 현기증, 소화 불량, 구토, 설사 등이 포함될 수 있다.The composition containing the herbal extract of the present invention has an antioxidative activity and can reduce the symptoms of hanging induced by inflammation caused by acetaldehyde and methanol generated in the alcohol body. In addition, it is possible to reduce hangover symptoms by increasing the activity of enzymes involved in the body's degradation of alcohol. The composition containing the herbal extract of the present invention can be administered orally before or after the ingestion of alcohol to prevent, reduce and alleviate the symptoms of hangover, and also have a liver protecting effect for reducing liver damage caused by alcohol. Such hangover symptoms may include thirst after drinking, fatigue, deterioration in condition, decline in memory, dizziness, indigestion, vomiting, diarrhea and the like.
본 발명에 따른 복합 생약 추출물을 포함하는 조성물은 식품 조성물로 제조된다. 상기 식품 조성물이란 복합 생약 추출물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 경구투여를 위한 캡슐화, 분말화, 현탁액 등으로 제조한 것을 의미한다. 상기 식품 조성물의 형태는 경구투여되는 물질이라면 특별하게 한정되지 않으며, 예를 들면, 분말, 과립, 정제, 캅셀 또는 음료의 형태일 수 있다.The composition comprising the herbal extract of the invention according to the present invention is prepared from a food composition. The food composition means that the complex herbal extract is added to a food material such as beverage, tea, spice, gum, confectionery, or the like, or is prepared by encapsulation, powdering, suspension or the like for oral administration. The form of the food composition is not particularly limited as long as it is a substance to be orally administered, and may be in the form of, for example, a powder, a granule, a tablet, a capsule or a drink.
필요에 따라, 본 발명의 복합 생약 추출물을 포함하는 조성물은 식품 제조 시에 통상적으로 첨가되는 성분을 더 포함할 수 있다. 예를 들면, 아미노산, 탄수화물, 지방, 비타민 및 영양소를 포함할 수 있으나 이에 한정되는 것은 아니다. 숙취 해소 효능을 보다 향상시키기 위한 측면에서, 본 발명의 복합 생약 추출물을 포함하는 조성물은 헛개나무열매, 매실 등의 원액 또는 농축액을 더 포함할 수 있다. 상기 농축액은 공지된 방법으로 제조될 수 있다. 예를 들면, 원료를 열수추출, 설탕절임 추출 또는 원액 착즙하여 얻은 추출물을 농축하여 제조될 수 있다. 상기 농축은 농축기를 이용한 진공 저온농축, 고온농축, 감압농축 또는 동결농축 방법을 통해 수행될 수 있으며, 제조되는 농축액 용량이 농축 전 추출물 용량의 50%(v/v) 이하가 되도록 농축되는 것이 바람직하고, 40 내지 200 브릭스 일 수 있으나 이에 한정되는 것은 아니다. 또한, 섭취시의 기호도를 향상시키기 위한 측면에서, 본 발명의 복합 생약 추출물을 포함하는 조성물은 과일 원액 또는 농축액, 감초 원액 또는 농축액, 감미제 등을 더 포함할 수 있다. 상기 감미제로는 예를 들면, 벌꿀, 아가베 시럽, 결정과당, 구연산 등이 있으나 이에 한정되는 것은 아니다. 상품성을 향상시키고 웰빙-친환경 트렌드에 부합하는 제품을 제조하기 위하여, 합성착향료 또는 보존료는 포함하지 않는 것이 바람직하다. 복합 생약 추출물 및 상기의 통상적으로 첨가되는 성분을 혼합하여 본 발명의 복합 생약 추출물을 포함하는 조성물을 제조할 수 있다. 예를 들면, 제조되는 조성물 100중량부에 대하여 복합 생약 추출물 1 내지 3 중량부, 과일농축액 0.5 내지 5 중량부, 헛개나무열매 농축액 1 내지 5 중량부, 매실 농축액 0.1 내지 1 중량부, 감초 농축액 0.01 내지 0.1 중량부, 아미노산 0.1 내지 0.5 중량부, 비타민 0.00001 내지 0.001 중량부 및 감미제 10 내지 15 중량부의 조성으로 포함하도록 혼합하여 제조할 수 있으나 이에 한정되는 것은 아니다.If necessary, the composition containing the herbal extract of the present invention may further comprise components that are ordinarily added during the manufacture of food. But are not limited to, for example, amino acids, carbohydrates, fats, vitamins and nutrients. From the viewpoint of further improving the hangover efficacy, the composition comprising the herbal extract of the present invention may further comprise a stock solution or concentrate such as hornbug fruit, plum or the like. The concentrate can be prepared by a known method. For example, the extract can be prepared by concentrating the extract obtained by hot water extraction, sugar-picking, or stock solution from a raw material. The concentration can be carried out by vacuum low-temperature concentration, high-temperature concentration, reduced-pressure concentration or freeze-concentration method, and it is preferable that the concentration of the concentrate to be produced is concentrated so as to be 50% (v / v) And may be from 40 to 200 Bricks, but is not limited thereto. In addition, from the viewpoint of improving the preference at the time of ingestion, the composition comprising the herbal extract of the present invention may further comprise a fruit stock solution or concentrate, a licorice stock solution or concentrate, a sweetening agent and the like. Examples of the sweetening agent include, but are not limited to, honey, agave syrup, crystalline fructose, and citric acid. In order to improve the merchantability and produce a product that meets the well-being-environmentally friendly trend, it is preferable not to include a synthetic flavoring agent or preservative. A composition containing the herbal extract of the present invention can be prepared by mixing the herbal extract with the herb extract and the commonly added components. For example, 1 to 3 parts by weight of a complex herb extract, 0.5 to 5 parts by weight of a fruit concentrate, 1 to 5 parts by weight of a hornbill fruit concentrate, 0.1 to 1 part by weight of a plum concentrate, 0.01 to 1 part by weight of a licorice concentrate 0.1 to 0.5 parts by weight of amino acids, 0.00001 to 0.001 parts by weight of vitamins and 10 to 15 parts by weight of sweeteners, but the present invention is not limited thereto.
본 발명의 일 실시예에서, 상기 식품 조성물은 드링크제일 수 있다. 상기 드링크제는 향미제 또는 천연 탄수화물을 더 포함할 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등); 디사카라이드(예컨대, 말토스, 수크로오스 등); 올리고당; 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등); 및 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)로 이루어진 군에서 선택되는 적어도 하나일 수 있다. 상기 향미제로는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)를 단독으로 또는 혼합하여 이용할 수 있다.In one embodiment of the present invention, the food composition may be a drink. The drink may further contain flavors or natural carbohydrates. The natural carbohydrate may be monosaccharide (e.g., glucose, fructose, etc.); Disaccharides (e.g., maltose, sucrose, etc.); oligosaccharide; Polysaccharides (e.g., dextrin, cyclodextrin and the like); And sugar alcohols (e.g., xylitol, sorbitol, erythritol, etc.). As the flavor, natural flavoring agents (for example, tautatin, stevia extract, etc.) may be used alone or in combination.
이하, 본 발명의 이해를 돕기 위하여 본 발명을 하기 실시예에 의거하여 좀 더 상세하게 설명한다. 단, 이들 실시예는 본 발명을 예시하는 것일 뿐 첨부된 특허청구범위를 제한하는 것이 아니며, 본 발명의 범주 및 기술사상 범위 내에서 실시예에 대한 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in more detail with reference to the following examples. It will be apparent to those skilled in the art that these embodiments are illustrative of the present invention and are not intended to limit the scope of the appended claims and that various changes and modifications may be made to the embodiments within the scope and spirit of the invention , And it is natural that such variations and modifications fall within the scope of the appended claims.
실시예Example
<복합 생약 추출물의 제조를 위한 성분별 열수 추출물의 제조>≪ Preparation of hot water extract for each ingredient for preparing the herbal medicine extract >
건조하여 파쇄한 녹차종자, 어성초 및 연잎을 각각 1kg씩 준비한 후, 각 시료 중량에 대하여 20배수(v/w)의 정제수를 첨가하여 추출기기(Soxhelt heater, CHANGSHIN SCIENCE)를 이용하여 100℃온도조건에서 3시간 동안 추출하여 열수 추출물을 얻었다. 각 열수 추출물에 대하여 여과기기(Vacuum pump, Vision VS-97SM)로 여과후 감압농축기기(Rotavapor R-210, Heating bath B491, Vacuum Pump V700)로 55℃에서 농축하였으며, 동결건조기(Freeze dryer, ilShin FD8508)로 -50℃에서 7일간 건조하여 각 성분별 고형의 열수 추출물을 얻었다.1 kg of each of the green tea seeds, crustacea, and lotus leaves were crushed, and 20 times (v / w) of purified water was added to each sample weight. Using a Soxhelt heater (CHANGSHIN SCIENCE) For 3 hours to obtain hot water extract. Each of the hot-water extracts was filtered with a vacuum pump (Vision VS-97SM) and concentrated at 55 ° C using a rotary evaporator (Rotavapor R-210, heating bath B491, Vacuum Pump V700) FD8508) for 7 days at -50 < 0 > C to obtain a solid hot-water extract of each component.
<복합 생약 추출물의 제조를 위한 성분별 열수 추출물의 지표성분 분석><Analysis of Indicative Components of Hot Water Extracts by Ingredient for the Production of Combined Herb Medicine Extract>
숙취해소 식품 조성물의 제조를 위한 원료표준화의 일환으로 지표성분을 설정하여 각 성분별로 지표성분을 분석하였다.As a part of the standardization of raw materials for the preparation of the hangover - relieving food composition, the indicator components were set and the indicator components were analyzed for each component.
녹차종자의 지표성분 분석을 위한 성분으로는 EGC(Epicatechin gallete, C22H18O10) 성분을 선정하였다. 녹차종자 열수 추출물 800㎎에 메탄올을 첨가하여 30분간 초음파 추출하고 상온에서 안정화한 후 0.45㎛필터로 여과하여 얻은 용액을 희석용액으로 10배로 희석하여 얻은 용액을 액체크로마토그래피/자외부흡광광도검출기를 이용하여 최대흡수파장인 280nm에서 정량 분석하였다. HPLC 조건은 주입량 5㎕, 컬럼온도 40℃이고 이동상으로 0.1%(v/v)인산(A) 및 아세토나이트릴(B)를 이용하였다. 유속은 1.0㎖/min으로 하고, 시간별 이동상은 하기 표 1의 조건으로 수행하였다. 희석용액으로는 이동상 A와 B를 2:8의 비율로 혼합하여 제조한 것을 사용하였다.EGC (Epicatechin gallete, C 22 H 18 O 10 ) was selected as a component of the green tea seed. Methanol was added to 800 mg of green tea seed hot water extract, sonicated for 30 minutes, stabilized at room temperature, filtered through a 0.45 μm filter, diluted 10 times with diluted solution, and analyzed by liquid chromatography / ultraviolet absorption spectrophotometer And analyzed quantitatively at 280 nm, which is the maximum absorption wavelength. The HPLC conditions were as follows: an injection volume of 5 μl; column temperature of 40 ° C; 0.1% (v / v) phosphoric acid (A) and acetonitrile (B) as mobile phase. The flow rate was 1.0 ml / min, and the time-lapse mobile phase was performed under the conditions shown in Table 1 below. The diluted solution was prepared by mixing mobile phase A and B at a ratio of 2: 8.
5
25
27
400
5
25
27
40
5
40
5
55
5
40
5
5
95
60
95
9595
95
60
95
95
녹차종자 열수추출물의 분석결과, standard curve는 R2 값이 0.9993으로 정확하게 검량되었으며, 동결건조하여 얻은 녹차종자 열수추출물에서 EGC의 함량은 3589.26㎍/㎖이 검출되었다.Analysis of green tea seeds hot water extracts result, standard curve is R 2 value of 0.9993 was a precise calibration, the content of the EGC in the tea seed hot water extracts obtained by freeze-drying has been detected 3589.26㎍ / ㎖.
어성초의 지표성분 분석을 위한 성분으로는 하이페로시드(hyperoside, C21H20O12) 성분을 선정하였다. 어성초 열수 추출물 1g에 60% 농도의 메탄올 10㎖를 첨가하여 60분간 초음파 추출하고 상온에서 안정화한 후 0.45㎛필터로 여과하여 얻은 용액을 액체크로마토그래피/자외부흡광광도검출기를 이용하여 최대흡수파장인 362 nm에서 정량 분석하였다. HPLC 조건은 주입량 2㎕, 컬럼온도 40℃이고 이동상으로 0.1%인산(A) 및 아세토나이트릴(B)를 이용하였다. 유속은 1.0㎖/min으로 하고, 시간별 이동상은 하기 표 2의 조건으로 수행하였다.Hyperoside (C 21 H 20 O 12 ) component was selected as a component for the analysis of the surface component of Hwasungcho. 10 g of methanol at 60% concentration was added to 1 g of hot water extract, and the solution was sonicated for 60 minutes, stabilized at room temperature, filtered through a 0.45 μm filter, and analyzed by liquid chromatography / ultraviolet absorption spectrophotometer And quantitatively analyzed at 362 nm. HPLC conditions were 2 ㎕ injection volume,
10
40
42
50
50.2
600
10
40
42
50
50.2
60
15
25
100
100
15
1515
15
25
100
100
15
15
85
75
0
0
85
8585
85
75
0
0
85
85
어성초 열수추출물의 분석결과, standard curve는 R2 값이 0.9998로 정확하게 검량되었으며, 동결건조하여 얻은 어성초 열수추출물에서 하이페로시드의 함량은 208.85㎍/㎖이 검출되었다.As a result of analysis of the hydrothermal extract of Hwasungcho, the R 2 value of the standard curve was precisely calibrated to 0.9998, and the content of hyperferrocide was 208.85 ㎍ / ㎖ in the hydrothermal extract of Hwasungcho obtained by lyophilization.
연잎의 지표성분 분석을 위한 성분으로는 쿼세틴(quercetin, C16H10O7H2O) 성분을 선정하였다. 연잎 열수 추출물 300㎎에 전처리용액 10㎖를 가하여 60분간 90℃ 가열 수조 혹은 블록에서 가수분해반응시키고 상온에서 냉각한 후 메탄올로 1:1 희석한 후 액체크로마토그래피/자외부흡광광도검출기를 이용하여 최대흡수파장인 370 nm에서 정량 분석하였다. 전처리용액은 에탄올 100㎖, 증류수 40㎖ 및 염산 16㎖을 혼합하여 제조하였다. HPLC 조건은 주입량 10㎕, 컬럼온도 40℃이고 이동상으로 0.1%인산(A) 및 메탄올(B)을 이용하였다. 유속은 1.0㎖/min으로 하고, 시간별 이동상은 하기 표 3의 조건으로 수행하였다.Quercetin (C 16 H 10 O 7 H 2 O) was selected as an ingredient for analyzing the surface component of the lotus leaf. 10 mg of pretreatment solution was added to 300 mg of leafy hot water extract, and hydrolysis was carried out in a heating water bath or block at 90 ° C for 60 minutes. After cooling at room temperature, it was diluted 1: 1 with methanol and analyzed by liquid chromatography / ultraviolet absorption spectrophotometer And quantitatively analyzed at a maximum absorption wavelength of 370 nm. The pretreatment solution was prepared by mixing 100 ml of ethanol, 40 ml of distilled water and 16 ml of hydrochloric acid. The HPLC conditions were as follows: an injection volume of 10 μl, a column temperature of 40 ° C and 0.1% phosphoric acid (A) and methanol (B) as mobile phase. The flow rate was 1.0 ml / min, and the mobile phase by time was performed under the conditions shown in Table 3 below.
5
25
33
33.2
400
5
25
33
33.2
40
30
90
90
30
3030
30
90
90
30
30
70
10
10
70
7070
70
10
10
70
70
연잎 열수추출물의 분석결과, standard curve는 R2 값이 0.9999로 정확하게 검량되었으며, 동결건조하여 얻은 연잎 열수추출물에서 쿼세틴의 함량은 10194.94㎍/㎖이 검출되었다.The results of the lotus leaf hot water extract, standard curve is R 2 value of 0.9999 was a precise calibration, the content of kwosetin from lotus leaf hot water extract obtained by freeze-drying has been detected 10194.94㎍ / ㎖.
<복합 생약 추출물의 제조 및 성분분석>≪ Preparation and composition analysis of herbal medicine extracts >
녹차종자, 어성초 및 연잎 열수 추출물을 하기 표 4와 같은 성분비로 혼합하여 복합 생약 추출물을 제조하고, 페놀성 화합물 및 플라보노이드 함량을 측정하였다. 페놀성 화합물의 함량은 Folin-ciocalteu’s 비색법으로 측정하였다. 증류수에 녹인 복합 생약 추출물을 각각 50㎖ 튜브에 1㎖ 분주한 뒤 증류수 9㎖를 첨가한 후, 1㎖의 Folin-ciocalteu’s reagent를 첨가하고 잘 섞은 뒤 상온에서 5분간 방치하였다. 7% Na2CO3 10㎖을 첨가하였고 다시 증류수를 4㎖ 첨가하여 총 볼륨이 25㎖이 되게 한 후, 잘 섞어 상온에서 90분간 방치한 후 1시간 이내로 750nm에서 흡광도를 측정하였다. 갈산으로 작성된 표준곡선식을 이용하여 계산하였으며, 3회 이상 반복 실험하여 그 결과값을 평균값±표준편차로 제시하였다. 플라보노이드 함량은 Zhishen법으로 측정하였다. 증류수에 녹인 복합 생약 추출물 1㎖에 4㎖의 증류수를 첨가하고 5% NaNO2 0.3㎖을 넣어 잘 혼합한 후 상온에 6분간 방치하고, 10% AlCl3 0.3㎖을 첨가하여 용액을 잘 섞은 후 1 M NaOH 2㎖을 넣고, 증류수를 2.4㎖ 넣어 잘 혼합한 후 510nm에서 흡광도를 측정하였다. 시료의 총 플라보노이드 함량은 카테킨으로 작성된 표준곡선식을 이용하여 산출하였고, 3회 이상 반복 실험하여 그 결과값을 평균값±표준편차로 제시하였다.The extracts of green tea seeds, Rhizoctonia spp., And Yeast leaf extracts were mixed in the proportions shown in Table 4 below to prepare a herbal extract, and phenolic compounds and flavonoid contents were measured. The content of phenolic compounds was measured by Folin-ciocalteu's colorimetric method. 1 ml of the crude herb extract dissolved in distilled water was dispensed in 1 ml of 50 ml tube, 9 ml of distilled water was added, and 1 ml of Folin-ciocalteu's reagent was added, mixed well and left at room temperature for 5 minutes. 10 ml of 7% Na 2 CO 3 was added and 4 ml of distilled water was added to make a total volume of 25 ml. The mixture was kept at room temperature for 90 minutes and then absorbed at 750 nm within 1 hour. Calculation was performed using standard curve formulas. The results were repeated three times or more and the results were expressed as mean ± standard deviation. The content of flavonoid was measured by Zhishen method. Add 4 ml of distilled water to 1 ml of complex herb extract dissolved in distilled water, add 0.3 ml of 5% NaNO 2, mix well, leave at room temperature for 6 minutes, add 0.3 ml of 10% AlCl 3, mix well 2 ml of M NaOH was added, 2.4 ml of distilled water was added, and the absorbance was measured at 510 nm. The total flavonoid content of the sample was calculated using a standard curved formula prepared with catechin, and the results were repeated three times or more, and the result was expressed as a mean value ± standard deviation.
(wt%)Phenolic compound
(wt%)
(wt%)Flavonoid
(wt%)
표 4를 보면, 녹차 종자, 어성초 및 연잎 추출물을 1:2:1의 중량비로 혼합하여 제조된 제조예 3의 플라보노이드 함량이 가장 높은 것으로 나타났으며, 그 다음이 녹차 종자, 어성초 및 연잎 추출물을 1:2:2의 중량비로 혼합하여 제조된 제조예 2인 것으로 나타났다. 페놀성 화합물의 함량의 경우, 제조예 2에서 가장 높은 것으로 나타났으며, 그 다음이 제조예3인 것으로 나타났다. 제조예 1 및 4의 경우, 페놀성 화합물 함량은 6wt% 미만, 플라보노이드 함량은 5wt% 미만으로 제조예 2 및 3에 비하여 낮은 것으로 나타났다.Table 4 shows that the content of the flavonoid of Preparation Example 3, which was prepared by mixing the green tea seeds, the perch and the lotus leaf extract at a weight ratio of 1: 2: 1, was the highest, followed by the green tea seeds, 1: 2: 2 by weight. The content of the phenolic compound was the highest in Production Example 2, and the following was Production Example 3. In the case of Production Examples 1 and 4, the phenolic compound content was less than 6 wt% and the flavonoid content was less than 5 wt%, which was lower than those of Production Examples 2 and 3.
<복합 생약 추출물의 라디컬 소거활성 측정><Measurement of radical scavenging activity of herbal medicine extract>
상기 표 4의 제조예1 내지 4에 대하여 라디칼 소거활성을 측정하였다. DPPH 라디칼 소거활성은 Brand-Williams의 방법을 변형하여 측정하였다. 각 제조예에 증류수를 첨가한 후, 0.02 ㎖을 취하여 0.1 mM DPPH 0.38 ㎖을 혼합하여 상온에서 30분간 방치한 후 517nm에서 흡광도를 측정하였다. ABTs 라디칼 소거활성은 Pellegrini 등의 방법을 변형하여 측정하였다. 먼저 7.4mM ABTs와 2.6 mM potassium persulphate를 혼합하고 24시간 암소에 방치하여 청록색의 ABTs+ radical을 형성시키고, 이를 냉장고에 보관하여 준비한다(stock solution). Stock solution과 PBS를 70:1로 희석한 후 이 용액 390㎕에 증류수에 녹인 각 제조예 10㎕를 첨가한 뒤 바로 734 nm에서 흡광도를 측정하였다. 대조군으로는 증류수를 사용하였고, 양성대조군은 비타민 C를 이용하였으며, 3회 이상 반복 실험하여 그 결과 값을 평균값±표준편차로 제시하였다. DPPH 라디칼 소거활성은 하기 수학식 1을 이용하여 계산하고, 그 결과를 도 1에 도시하였다. ABTs 라디칼 소거활성은 하기 수학식 2를 이용하여 계산하고, 그 결과를 도 2에 도시하였다. The radical scavenging activity was measured for Production Examples 1 to 4 in Table 4 above. The DPPH radical scavenging activity was measured by changing the method of Brand-Williams. After adding distilled water to each of the preparation examples, 0.02 ml of 0.1 mM DPPH was mixed with 0.38 ml of the solution, and the mixture was allowed to stand at room temperature for 30 minutes, and the absorbance was measured at 517 nm. The ABTs radical scavenging activity was measured by modifying the method of Pellegrini et al. First, 7.4 mM ABTs and 2.6 mM potassium persulphate are mixed and allowed to stand in a dark place for 24 hours to form cyan-colored ABTs + radicals, which are then stored in a refrigerator (stock solution). Stock solution and PBS were diluted to 70: 1, and 10 μl of each preparation dissolved in distilled water was added to 390 μl of this solution, and then absorbance was measured at 734 nm immediately. Distilled water was used as a control group and vitamin C was used as a positive control group. The results were repeated three times or more and the results were expressed as mean ± standard deviation. The DPPH radical scavenging activity was calculated using the following equation (1), and the results are shown in FIG. The ABTs radical scavenging activity was calculated using the following equation (2), and the results are shown in FIG.
도 1을 보면, 제조예 3의 활성이 61.43±2.94%로 가장 우수하고, 제조예 2 55.73±0.33%, 제조예 1 52.07±0.70%의 순으로 활성이 우수한 것으로 나타났다.1 shows that the activity of Preparation Example 3 is the highest at 61.43 ± 2.94%, that of Production Example 2 is 55.73 ± 0.33%, and that of Production Example 1 is 52.07 ± 0.70%.
도 2를 보면, 제조예 3의 활성이 63.91±1.34%로 가장 우수하고, 제조예 2 59.62±2.22%, 제조예 1 53.81±1.60%의 순으로 활성이 우수한 것으로 나타났다.2 shows that the activity of Preparation Example 3 was the highest at 63.91 ± 1.34%, that of Production Example 2 was 59.62 ± 2.22%, and that of Production Example 1 was 53.81 ± 1.60%.
<복합 생약 추출물의 알코올 분해 활성 측정><Measurement of alcohol decomposition activity of herbal medicine extract>
복합 생약 추출물의 알코올 분해 활성은 in vitro에서 ADH 및 ALDH의 활성을 먼저 측정하여 확인하였다. ADH 활성은 증류수, tris-HCl buffer(pH 8.0), 20 mM NAD+, 에탄올의 혼합액에 증류수에 녹인 상기 제조예3을 첨가하고 S9 homogenates 효소원을 반응시키고 30℃에서 5분간 preincubation 한 후, 5분간 340nm에서의 흡광도의 변화를 측정하여 확인하였다. ALDH 활성은 증류수, tris-HCl buffer(pH 8.8), 20mM NAD+, 1M acetaldehyde, 0.33M 2-머캅토에탄올의 혼합액에 증류수로 녹인 150㎍/㎖ 농도의 상기 제조예3을 첨가하고 S9 homogenates 효소원을 반응시키고, 30℃에서 5분간 preincubation 한 후, 5분간 340nm에서의 흡광도의 변화를 측정하여 확인하였다. 시료를 첨가하지 않는 것을 대조군으로 하여 시료의 ADH 및 ALDH 활성은 대조군 대비 상대활성(%)으로 제시하였고, 3회 이상 반복 실험하여 그 결과 값을 평균값±표준편차로 제시하였다. ADH활성을 측정한 결과는 도 3에, ALDH 활성을 측정한 결과는 도 4에 도시하였다.Alcohololytic activity of the herbal extracts was determined by measuring the activity of ADH and ALDH in vitro . The ADH activity was obtained by adding the above Preparation Example 3 dissolved in distilled water to a mixed solution of distilled water, tris-HCl buffer (pH 8.0), 20 mM NAD +, and ethanol, reacting with an S9 homogenates enzyme source, preincubating at 30 ° C for 5 minutes, The change in absorbance at 340 nm was measured and confirmed. ALDH activity was measured by adding the above Preparation Example 3 at a concentration of 150 μg / ml dissolved in distilled water, a mixture of tris-HCl buffer (pH 8.8), 20 mM NAD +, 1 M acetaldehyde and 0.33 M 2-mercaptoethanol, , Preincubation at 30 ° C for 5 minutes, and then measuring the change in absorbance at 340 nm for 5 minutes. The ADH and ALDH activities of the samples were shown as relative activity (%) relative to the control group. The results were repeated three times or more and the results were expressed as mean ± standard deviation. ADH activity was measured in FIG. 3, and ALDH activity was measured in FIG.
도 3 및 4를 보면, 복합 생약 추출물은 알코올 대사에 관련된 ADH 와 ALDH 활성을 모두 증가시키는 것으로 나타났다. Referring to FIGS. 3 and 4, the herbal extracts of both herbs showed an increase in both ADH and ALDH activities related to alcohol metabolism.
<복합 생약 추출물의 독성평가><Toxicity evaluation of herbal medicine extract>
유효성분의 함량이 높고 항산화 효능이 우수한 본 발명의 조성물인 제조예3에 대하여, in vivo 에서의 효능을 측정하기 앞서 독성평가실험을 수행하였다. 실험동물은 SPF(Specific pathogen free)의 4주령 ICR 웅성마우스를 구입하여 사용하였다((주) 오리엔트바이오, 경기도). 실험동물은 항온항습시스템을 갖춘 후드 내에서 5 내지 6마리를 polycarbonate cage (278×420×200 mm)에 넣고, 실내온도 22±2℃, 기류속도 13 내지 18cm/sec, 환기횟수 10 내지 20회/h, 기압차2 내지 10mm H2O, 명암주기 12시간; 7:00 내지 19:00, 조도 150 내지 300Lux에서 사육하였다. 일주일에 2번씩 체중을 측정하여 정기적으로 외관을 관찰하고, 주기적으로 베딩을 갈아주어 청결을 유지하였다. 식이는 AIN-76으로 충분히 공급하고, 식수로는 멸균한 증류수를 이용하였다. 1주일간의 예비사육기간을 가진 후, 각 투여군 당 마리의 체중 평균값이 같도록 그룹화한 후 0, 250, 500, 750, 1000, 1500, 2000 mg/kg body weight(b.w.)/day 조건으로 제조예 3을 증류수에 녹여 경구투여 하였다. 경구 투여 익일 매일 1회씩 최종 14일간 관찰하였으며, 해부는 12시간 절식하고 이산화탄소를 이용하여 마취한 후 개복하였다. 해부시 간, 신장, 비장을 적출한 뒤, 각 조직의 무게를 측정하고, 하기 수학식 3을 이용해 체중에 상응하는 조직무게를 계산하였다. High content of the active ingredient with respect to
혈청은 복대동맥에서 채혈하여 3,000rpm에서 15분간 원심분리하여 -70℃ 냉동고에 보관하여 사용하였다. 상용화된 키트(Asan Pharmaceutical, Seoul, Korea)를 사용하여 혈청 ALT 및 AST를 측정하여 독성을 평가하였다. 활성도의 단위는 Karmen/㎖으로 제시하고, 실험의 결과는 평균±표준편차(mean±S.E.)로 나타내었다. 동물실험에서 각 군의 차이는 ANOVA-test로 분석 후 p<0.05 수준에서 Duncan's multiple range test에 의해 검정하였다. 실험동물의 체중, 조직무게, 혈청 평가 결과는 하기 표 5 내지 7에 나타냈다.Serum was collected from the abdominal aorta and centrifuged at 3,000 rpm for 15 minutes and stored in a -70 ° C freezer. Serum ALT and AST were measured using a commercial kit (Asan Pharmaceutical, Seoul, Korea) to evaluate toxicity. The unit of activity is given as Karmen / ml and the results are expressed as mean ± standard deviation (mean ± SE). The differences between the groups were analyzed by ANOVA-test and Duncan's multiple range test at p <0.05. The body weight, tissue weight and serum evaluation results of the experimental animals are shown in Tables 5 to 7 below.
(mg/kg·bw/day)Dosage by Ingredient
(mg / kg · bw / day)
Production Example 3
(mg/kg·bw/day)Dosage by Ingredient
(mg / kg · bw / day)
Production Example 3
(mg/kg·bw/day)Dosage by Ingredient
(mg / kg · bw / day)
(Karmen/㎖)ALT
(Karmen / ml)
(Karmen/㎖)AST
(Karmen / ml)
Production Example 3
표 5 내지 7을 참고하면, 모든 실험군에 있어서 체중, 조직무게, 혈청 ALT 및 AST활성에 영향을 나타내지 않는 것을 확인할 수 있다.Referring to Tables 5 to 7, it can be seen that all the experimental groups do not show any influence on body weight, tissue weight, serum ALT and AST activity.
<복합 생약 추출물의 숙취 생리활성평가><Estimation of hangover physiological activity of herbal extracts>
효능이 우수한 제조예 3에 대하여, in vivo 에서의 효능을 측정하기 위한 실험을 수행하였다. 실험동물은 SPF (Specific pathogen free)의 8주령 웅성 Sprague-Dawley rat을 구입하여 실험에 사용하였다((주) 오리엔트바이오, 경기도). 실험동물은 항온항습시스템을 갖춘 후드 내에서 4마리를 polycarbonate cage (278×420×200 mm)에 넣고, 실내온도 22±2℃, 기류속도 13 내지 18cm/sec, 환기횟수 10 내지 20회/h, 기압차 2 내지 10mm H2O, 명암주기 12시간; 7:00 내지 19:00, 조도 150 내지 300 Lux에서 사육하였다. 주기적으로 베딩을 갈아주어 청결을 유지하였다. 식이는 상용화된 pellet chow를 공급하고, 실험기간동안 사료와 급수 제한을 두지 않았다. 1주일 동안 사육환경에 적응시킨 후, 몸무게가 동일하게 8마리로 무작위로 배정하여 군으로 나누었다. 정상대조군, 에탄올군 및 제조예 3의 실험군으로 그룹화하였다.For Preparation Example 3, which has excellent efficacy, in vivo In order to determine the efficacy of the test. An 8-week-old male Sprague-Dawley rats of SPF (Specific pathogen free) were purchased from the experimental animals (Orient Bio Co., Ltd., Gyeonggi-do). The animals were housed in a polycarbonate cage (278 × 420 × 200 mm) in a hood equipped with a constant-temperature and constant-humidity system and incubated at room temperature 22 ± 2 ° C, air velocity 13 to 18 cm / sec,
숙취 실험 전날, 사료 섭취로 인한 위장관의 에탄올 흡수 방해를 막기 위해 시료 투여 전 18시간동안 절식시켰다. 정상대조군과 에탄올군은 멸균증류수를 경구투여하였고, 실험군은 200mg/kg·b.w./day 제조예 3을 경구투여하였다. 각 시료를 투여한 30분 후에, 에탄올군 및 실험군에 25% ethanol(3 g/kg·b.w./day)을 10 ㎖/kg으로 경구투여 하였다. 각 제조예는 증류수에 녹여 투여하였다. 이후 3 g/kg·b.w./day 에탄올을 경구투여 한 후, 1시간, 3시간, 5시간에 미동맥에서 채혈을 실시하였다. 시간별로 획득한 혈액은 4℃, 3,000 rpm에서 10분간 원심분리하여 혈청을 얻었다. 7시간에 실험동물을 이산화탄소로 마취시킨 후, 해부하여 조직을 적출하였다. On the day before the hangover experiment, the animals were fasted for 18 hours before the administration of the sample to prevent interference with the ethanol absorption of the gastrointestinal tract due to feed intake. In the normal control group and the ethanol group, sterilized distilled water was orally administered. In the experimental group, 200 mg / kg b.w./day Preparation Example 3 was orally administered. Twenty minutes after the administration of each sample, 25% ethanol (3 g / kg · b.w./day) was orally administered at 10 ml / kg to the ethanol group and the experimental group. Each preparation was dissolved in distilled water and administered. After oral administration of 3 g / kg · b · w · / day ethanol, blood samples were collected from the American artery at 1 hour, 3 hours, and 5 hours. Blood obtained by time was centrifuged at 3,000 rpm at 4 ° C for 10 minutes to obtain serum. At 7 hours, the animals were anesthetized with carbon dioxide, dissected and tissues were extracted.
혈중 에탄올 및 아세트알데히드 함량은 시간별로 채취한 혈청을 대상으로 에탄올 및 아세트알데히드 측정용 assay kit(Roche Co., Darmstadt, Germany)를 사용하여 분광광도계(Bio-Tek, Winooski, VT, USA)를 이용하여 측정하고, 각 군의 데이터는 1시간의 측정한 에탄올군의 혈청 에탄올 및 아세트알데히드 함량을 기준으로 상대활성(%)으로 제시하였다. 혈중 에탄올 농도의 변화는 도 5에 도시하고, 아세트알데히드 농도의 변화는 도 6에 도시하였다.The ethanol and acetaldehyde contents in blood were measured by using a spectrophotometer (Bio-Tek, Winooski, VT, USA) using the assay kit for measuring ethanol and acetaldehyde (Roche Co., Darmstadt, Germany) , And data of each group were presented as relative activity (%) based on the serum ethanol and acetaldehyde contents of the ethanol group measured for 1 hour. The change in the blood ethanol concentration is shown in Fig. 5, and the change in the acetaldehyde concentration is shown in Fig.
적출한 간조직에 대하여는 -70℃에 보관한 경우 해동하여 D-PBS로 3회 세척한 후 조직 무게(g) 10배의 0.1 M Tris-HCl buffer(pH 7.4)를 가하고 빙냉 하에서 유리-테프론 분쇄기로 균질화하여 시료를 준비한 후 assay kit(Biovision, Mountain View, CA, USA)을 사용하여 ADH 및 ALDH 활성을 측정하였고, 각 kit에서 제시한 계산식을 이용하여 nmol/min/㎖로 제시하였다. 또한, 간세포의 손상을 확인하기 위해 혈청 AST 및 ALT를 측정하였다. 간세포 손상은 수송기능 및 막 투과성에 변화를 초래하여 결국 세포로부터 효소들의 혈액으로의 누출이 발생하게 되므로, ALT 및 AST 의 순환계로의 많은 방출은 알코올에 의한 독성화 과정동안에 간 조직 막의 심각한 손상을 의미한다. 해부 시 채취한 혈액을 3,000 rpm에서 20 min 동안 원심분리 한 후, 상층액으로부터 혈청을 획득하고 상용화된 키트(Asan Pharmaceutical, Seoul, Korea)를 사용하여 ALT와 AST 활성을 분석하였고, 그 활성도의 단위는 Karmen/㎖으로 제시하였다. 적출한 조직의 상대적 무게는 표 8에 나타내고, 혈청의 AST 및 ALT의 활성을 측정한 결과는 표 9에, 간조직의 ADH 및 ALDH 활성을 측정한 결과는 표 10에 나타냈다.For the extracted liver tissues, when stored at -70 ° C, the cells were thawed and washed three times with D-PBS, and 0.1 M Tris-HCl buffer (pH 7.4) 10 times the tissue weight (g) was added. , And then ADH and ALDH activities were measured using an assay kit (Biovision, Mountain View, Calif., USA). The results were expressed in terms of nmol / min / ml using the equations given in the kit. Serum AST and ALT were also measured to confirm damage of hepatocytes. Since hepatocyte damage leads to changes in transport function and membrane permeability resulting in leakage of enzymes from the cells into the blood, many releases of ALT and AST into the circulatory system cause serious damage to the liver tissue during the alcohol- it means. Blood collected at the time of dissection was centrifuged at 3,000 rpm for 20 min, serum was obtained from the supernatant, and ALT and AST activities were analyzed using a commercial kit (Asan Pharmaceutical, Seoul, Korea) Was given as Karmen / ml. The relative weights of the extracted tissues are shown in Table 8. The results of measuring the activity of AST and ALT of serum are shown in Table 9, and the results of ADH and ALDH activities of liver tissues are shown in Table 10.
모든 실험의 결과는 평균±표준편차(mean±S.E.)로 나타내었다. 동물실험에서 각 군의 차이는 ANOVA-test로 분석 후 p<0.05 수준에서 Duncan's multiple range test에 의해 검정하였다. The results of all experiments were expressed as mean ± standard deviation (mean ± SE). The differences between the groups were analyzed by ANOVA-test and Duncan's multiple range test at p <0.05.
Experimental group
(nmol/min/㎖)ADH activity
(nmol / min / ml)
(nmol/min/㎖)ALDH activity
(nmol / min / ml)
도 5 및 6을 보면, 본 발명의 복합 생약 추출물 제조예 3을 경구투여한 실험군은 알코올 투여 후 3시간과 5시간에서 에탄올군과 비교하여 혈중 에탄올 농도 및 혈중 아세트알데히드 농도가 통계적으로 유의하게 감소한 것을 확인할 수 있다. 아세트알데히드 농도의 경우, 실험군에서 제조예 3 투여후 3시간 경과 후부터 정상대조군과 유사한 수준으로 감소하는 것으로 나타나, 이로부터 본 발명에 따른 조성물이 아세트알데히드로 유발되는 숙취증상의 예방, 저감 및 해소에 우수한 효과를 갖는 것을 확인할 수 있다.5 and 6, in the group administered orally administered with the herbal extract preparation of the present invention, the ethanol concentration and the blood acetaldehyde concentration in the blood were significantly lowered in comparison with the ethanol group at 3 hours and 5 hours after the alcohol administration . The acetaldehyde concentration was decreased to a level similar to that of the normal control group after 3 hours from the administration of Preparation Example 3 in the experimental group. This shows that the composition according to the present invention is effective in preventing, reducing and eliminating acetaldehyde-induced hangover symptoms It can be confirmed that it has an excellent effect.
표 8 및 9를 참고하면, 제조예 3을 경구투여한 실험군은 급성 알코올 투여에 따른 실험군간 장기무게의 차이는 나타나지 않으며, 급성 알코올의 투여가 7시간 이후 해부한 혈청의 ALT 및 AST 활성에 영향을 미치지 않음을 확인할 수 있다. As shown in Tables 8 and 9, no significant difference in organ weight was observed between the experimental group administered with the acute alcohol and the ALT and AST activity of the serum dissected after 7 hours of acute alcohol administration It is possible to confirm that it does not exceed.
표 10을 참고하면, 급성 알코올 투여에 따라 ADH 및 ALDH 활성이 감소하는 에탄올군과 비교하였을 때, 제조예 3을 경구투여한 실험군의 ADH 및 ALDH 활성은 모두 통계적으로 유의하게 증가하는 것을 확인할 수 있다.As shown in Table 10, the ADH and ALDH activities of the test group orally administered in Preparation Example 3 were significantly increased in comparison with the ethanol group in which the ADH and ALDH activities were decreased by acute alcohol administration .
<복합 생약 추출물을 포함하는 과립형 조성물의 제조>≪ Preparation of granular composition containing complex herbal extracts >
본 발명의 복합 생약 추출물 제조예 3을 포함하는 식품 조성물을 하기 표 11의 조성비에 따라 경구투여가 용이한 과립형상 제형으로 제조하였다. 섭취량은 안전성 확보를 위하여 복합 생약 추출물은 통상적으로 섭취하는 양 이하의 수준에서 in vivo에 효능을 보이는 농도로 환산하여 하루 1,000 mg을 섭취하도록 설정하였으며, 알당 500 mg/2회/day로 설계하였다. 색상은 본 약제 내 추출물의 색을 감추기 위하여 치자 레드와 치자 블루를 이용하여 적정의 정제 코팅 필름 색 배합을 진행하였다. The food composition comprising the herbal extract preparation example 3 of the present invention was prepared into a granular formulation easy to be orally administered according to the composition ratio shown in Table 11 below. In order to ensure safety, the herbal extracts of the herbal medicines were set to be taken at a dose of 1,000 mg / day in terms of the in vivo efficacy at a level below the usual intake level, and were designed with 500 mg / In order to hide the color of the extract in the present invention, the color of tablets coated with red ginger and gardenia blue was adjusted.
<복합 생약 추출물을 포함하는 음료의 제조>≪ Preparation of beverage containing complex herbal medicine extract >
본 발명의 복합 생약 추출물 제조예 3을 포함하는 식품 조성물을 하기 표 12의 조성비에 따라 혼합하여 경구투여가 용이한 음료의 형태로 제조하였다. 시중 판매되는 숙취해소 음료를 기준으로 하루 50㎖ 섭취하도록 용량을 설정하였다. 기능성을 보다 향상시키기 위하여 헛개나무 열매 추출 농축액을 첨가하고, 건강지향적 컨셉으로 합성 착향료 또는 보존료를 제외하여 제조하였다. 벌꿀, 구연산을 이용하여 감미 15 브릭스 및 산미 pH3.7로 조절하였다. 보다 풍미 및 기호성을 향상시키기 위하여 과일농축액을 첨가하였다. 모든 농축액은 시중에 판매되는 제품을 구입하여 사용하였다.The food composition containing the herbal extract preparation example 3 of the present invention was mixed according to the composition ratios shown in Table 12 below, and was prepared in the form of a drink which can be easily administered orally. The dose was set to be 50 ml per day based on the commercially available hangover-free beverage. In order to improve the functionality, Hovenia dulcis extract was added and the synthetic flavor or preservative was excluded as a health - oriented concept. Honey and citric acid were used to adjust the sweetness 15 Brrix and acidity to pH 3.7. Fruit concentrate was added to improve flavor and palatability. All concentrates were purchased and used on the market.
상기 음료조성물 1 및 2에 대하여, 시장성(상품성)을 평가하기 위한 기호도 관능 테스트를 수행하였다. 관능 테스트 방법에 대한 교육을 이수 받은 사내 평가단을 대상으로 하였으며, 제시된 모든 시료는 평가 전 정수로 입을 헹구도록 한 다음, 평가를 진행하도록 하였다. 관능 테스트 항목은 맛, 기호도, 향 등을 포함하여 총 7개 항목이었으며, 7점 척도 평가법을 이용하였다. 통계처리는 SAS 통계프로그램을 이용하여 ANOVA로 각 실험군 간의 평가 결과 비교 분석을 수행하였고, 5% 유의수준에서 Duncan's multiple range test를 이용하여 유의성을 검증하였으며, 그 결과를 표 13 및 도 7에 나타냈다.The
성별rater
gender
기호도Overall
Likelihood
해소감hangover
표 13 및 도 7을 보면, 과일농축액으로 체리농축액을 포함하는 음료조성물 1이 배농축액을 포함하는 음료조성물 2보다 높은 기호도를 갖는 것으로 나타났다. 산미는 체리농축액을 포함하는 음료조성물 1에 대해 여성이 가장 높은 기호도를 나타냈으며 단 맛에서는 남녀 모두 음료조성물 1에서 높은 기호도를 보였다. 통계적으로 확인한 결과, 산미와 단 맛 모두 음료조성물 1이 음료조성물 2보다 유의적으로 높은 기호도를 보이는 것으로 나타났다. 전반적인 기호도에서도 음료조성물 1을 섭취한 여성이 6.2점으로 가장 점수가 높았으며, 남성이 5.8점으로 그 다음으로 높게 나타났다. 이는 산미와 단미의 기호도와 비슷한 경향을 나타나, 전반적인 맛에 대한 기호가 산과 당에 따라 영향을 주는 것으로 파악된다. Referring to Table 13 and FIG. 7, it was found that
Claims (7)
20 to 30 parts by weight of a green tea seed hydrothermal extract, 40 to 60 parts by weight of a hydrothermal extract of Horseshoe cherry, and 20 to 30 parts by weight of a hot water extract of a leafy leaf as an active ingredient.
[Claim 2] The method according to claim 1, wherein the green tea seed hydrothermal extract, Hodgson chrysanthemum extract and hot water extract of Leaf Leaf are prepared by adding a solvent of 10 to 20 times the weight of the extractant and extracting the mixture at 90 to 100 DEG C for 2 to 4 hours ≪ / RTI >
[2] The composition according to claim 1, wherein the complex herbal extract has a flavonoid content of 5 to 7 wt%.
The food composition for hangover as claimed in claim 1, further comprising a fruit concentrate, a Hovenia dulken concentrate, a plum concentrate, a licorice concentrate, an amino acid, a vitamin and a sweetener.
The food composition according to claim 4, wherein the fruit concentrate is a cherry concentrate.
[3] The composition according to claim 1, which comprises 1 to 3 parts by weight of the herbal extract, 0.5 to 5 parts by weight of the fruit concentrate, 1 to 5 parts by weight of the fruit concentrate, 0.1 to 1 part by weight of the plum concentrate, 0.01 to 0.1 part by weight, 0.1 to 0.5 part by weight of amino acid, 0.00001 to 0.001 part by weight of vitamin and 10 to 15 parts by weight of sweetener.
The food composition for hangover as claimed in claim 1, wherein the food composition is in the form of powder, granules, tablets, capsules or drinks.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160097548A KR20180013603A (en) | 2016-07-29 | 2016-07-29 | Alcohol detoxification composition comprising extract of natural herb |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160097548A KR20180013603A (en) | 2016-07-29 | 2016-07-29 | Alcohol detoxification composition comprising extract of natural herb |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20180013603A true KR20180013603A (en) | 2018-02-07 |
Family
ID=61204002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160097548A KR20180013603A (en) | 2016-07-29 | 2016-07-29 | Alcohol detoxification composition comprising extract of natural herb |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20180013603A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021107233A1 (en) * | 2019-11-29 | 2021-06-03 | 농업회사법인 주식회사 그린벨트의 친구들 | Health functional composition comprising natural composite materials, and preparation method therefor |
-
2016
- 2016-07-29 KR KR1020160097548A patent/KR20180013603A/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021107233A1 (en) * | 2019-11-29 | 2021-06-03 | 농업회사법인 주식회사 그린벨트의 친구들 | Health functional composition comprising natural composite materials, and preparation method therefor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI500391B (en) | Composition for reliving and preventing hangover and beverage comprising composition | |
KR101144059B1 (en) | Composition for prevention or treatment of diabete or obesity comprising Punica granatum extract and red ginseng extract | |
KR20140090453A (en) | Composition comprising aronia extract for preventing and relieving hangover, and for protecting the alcohol-damaged hepatocyte | |
KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
KR20160117034A (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
KR101093998B1 (en) | Functional composition for the prevention of hangover and improving liver function | |
KR100976241B1 (en) | Extract of sedum sarmentosum for alcohol oxidation and relieves hangover | |
KR101371143B1 (en) | Composition comprising chlorella for improving liver function or relieving hangover | |
KR101212706B1 (en) | Production method of anti-obesity beverage using seaweed extracts | |
JP2010275288A (en) | Functional composition for preventing and improving hangover, food and food additive containing the same | |
KR20180013603A (en) | Alcohol detoxification composition comprising extract of natural herb | |
KR20170086198A (en) | Manufacturing method of diet solid tea including fermentation herb remedy and dietary fiber and the solid tea produced thereby | |
KR101034986B1 (en) | Composition comprising the mixed herbal extract for relieving hangover | |
KR20090081062A (en) | A diabetes pharmaceutical composition and manufacturing process thereof | |
KR20200053016A (en) | Pharnaceutical composition for prevention or treatment of diabetes comprising the mixed extract of vegetable natural products having the effect on removal of swelling and health functional food for prevention or improvement of diabetes comprising the same | |
KR101668447B1 (en) | Composition for curing hanover and health functional foods composition comprising the same | |
KR20190006702A (en) | Method for manufacturing the functional beverage containing Chaenomeles sinensis Koehne, Mentha arvensis var and Cornus officinalis sieb and the functional beverage prepared therefrom | |
KR20050100890A (en) | Composition comprising the extract of acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
KR101935861B1 (en) | Functional food composition for removing hangover and improving liver function and manufacturing method for thereof | |
KR100872310B1 (en) | Functional composition for the cotinene metabolism improvement which is caused by with smoking and hangover removal, foods and food additive containing the same | |
KR20070110689A (en) | Pharmaceutical composition comprising an extract of prunus persica l preventing from hepatotoxicity and nephrotoxicity induced by anticancer agent | |
KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
US20040156924A1 (en) | Vitamin C and calcium ascorbate based dietary supplement products | |
KR20130091387A (en) | Red ginseng sport beverage comprising panax ginseng concentrate and fruit concentrate | |
KR20130031560A (en) | Composition for eliminating hangover comprising stems bud of hovenia dulcis and pueraria flos as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |